CD5-targeted CAR T-cells for relapsed/refractory T-ALL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of immune therapy—called CD5-targeting CAR T-cells—for people with a hard-to-treat form of T-cell acute lymphoblastic leukemia. It aims to see if these specially designed cells can find and destroy leukemia cells with the CD5 marker.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of leukemia called T-ALL that tests positive for CD5 protein on at least 90% of cancer cells.
- Your leukemia must have returned or not responded to standard treatments.
- Your cancer cells must still be detectable in your bone marrow (more than 5% or 1% by different tests).
- Your liver and kidney function must be within safe limits, and your heart must pump well (ejection fraction of 50% or higher).
- You must not have active infections or serious heart, brain, or immune system issues.
- You must be willing to use effective birth control for at least 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells, engineered to find and attack cancer cells that have a protein called CD5. It is for people with a type of T-cell lymphoma that has come back or not responded to other treatments.
This trial tests a new CAR-T cell treatment for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. It aims to see if these immune cells can safely and effectively fight the cancer.
This trial tests a new type of immune therapy called CAR T cells that are designed to find and attack cancer cells with a CD5 marker. It may be an option for people with T-cell leukemia or lymphoma that has not responded to standard treatments.
This trial tests a new immune cell therapy (CAR T-cells) that targets CD5 found on certain T-cell cancers. It may be an option for people whose cancer has not responded to other treatments.
This trial tests a new type of immune cell therapy (called CAR-T) that targets two proteins, CD5 and CD7, on the surface of T-cell leukemia or lymphoma cells. It may be an option for people whose cancer came back or didn't respond to standard treatment.
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are reprogrammed to find and destroy T-cell leukemia or lymphoma cells that have the CD5 protein. It may be an option if your cancer has come back or hasn't responded to other treatments.
Hear when a new T Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.